Echocardiographic Evaluation of Hypertensive Acute Pulmonary Edema
Acute cardiogenic pulmonary edema (ACPE), one of the most severe forms of acute heart failure, represents 5% of hospital admissions. One of the most frequent phenomena encountered during ACPE is hypertensive crisis (hypertensive ACPE) but the mechanisms and causes of hypertensive ACPE are insufficiently understood. Few studies have evaluated the cardiac function during hypertensive ACPE, and these studies used only conventional echocardiography methods. New methods of evaluation of cardiac function in hypertensive ACPE (such as Tissue Doppler imaging) have not been used.
The objectives of this study are to evaluate presence and role of the following potential mechanisms of hypertensive ACPE: 1. acute myocardial dysfunction (systolic and diastolic); 2. silent transient myocardial ischemia; 3. acute mechanical left ventricular dyssynchrony; 4. dynamic mitral regurgitation; 5. inter-ventricular interaction. Conventional and Tissue Doppler echocardiography will be used to assess cardiac function.
|Pulmonary Edema Hypertension|
|Study Design:||Observational Model: Case-Crossover
Time Perspective: Prospective
|Official Title:||Echocardiographic Evaluation of Hypertensive Acute Pulmonary Edema|
- acute myocardial dysfunction (systolic and diastolic) and/or dyssynchrony [ Time Frame: acute event and 48 to 96 h after the event ]
- surrogate markers of silent transient myocardial ischemia [ Time Frame: acute event and 48 to 96 h after the event ]
- dynamic mitral regurgitation [ Time Frame: acute event and 48 to 96 h after the event ]
- inter-ventricular interaction [ Time Frame: acute event and 48 to 96h after the event ]
|Study Start Date:||May 2008|
|Study Completion Date:||May 2009|
|Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
Patients with hypertensive (systolic blood pressure ≥160 mmHg) acute pulmonary edema, evaluated within 120 minutes after admittance.
The same patients from group 1 followed-up at 48 to 96 hours.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00829855
|Department of Cardiology, University and Emergency Hospital of Bucharest|
|Bucharest, Romania, 050098|
|Principal Investigator:||Mircea Cinteza, MD, PhD||University of Medicine and Pharmacy "Carol Davila" Bucharest|
|Principal Investigator:||Dragos Vinereanu, MD, PhD||University of Medicine and Pharmacy "Carol Davila" Bucharest|
|Study Chair:||Andrei D Margulescu, MD||University of Medicine and Pharmacy "Carol Davila" Bucharest|